Business Wire

Milrem: Leading European Defence Companies Submit a Project for an Unmanned Ground System to the European Commission

Share

A consortium led by the Estonian Milrem Robotics and composed of several major defence, communication and cybersecurity companies and high technology SMEs established in the EU submitted their application to the European Commission’s European Defence Industrial Development Programme (EDIDP) for a multi-mission unmanned ground system capable of being teamed with manned and aerial vehicles.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190924005469/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The system will consist of a robust and modular unmanned ground vehicle (UGV) equipped with an electronic warfare resistant command, control and communications solution and secure autonomous mobility software that enables the operator to simultaneously and safely control multiple land and air platforms. (Graphic: Business Wire)

The system will consist of a robust and modular unmanned ground vehicle (UGV) equipped with an electronic warfare resistant command, control and communications solution and secure autonomous mobility software that enables the operator to simultaneously and safely control multiple land and air platforms.

The UGVs will be able to team with manned and aerial vehicles with the objective to provide flexibility, modularity and versatility for different missions, increase protection, sustainability and performance of military operations and enhance situational awareness of ground forces.

During the project operational know-how will be gathered and concepts for the combined engagement of manned and unmanned assets developed, while taking into account the ethical aspects applicable to robotics, artificial intelligence and autonomous systems. State-of-the-art virtual and constructive simulation environments will also be set up.

The project is titled iMUGS (integrated Modular Unmanned Ground System) due to its origins at the Permanent Structured Cooperation (PESCO) framework. The iMUGS project was officially adopted by 25 EU defence Ministers on the updated list of projects for PESCO in November 2018. It is led by Estonia and technical requirements have also been agreed with Finland, Latvia, Germany, Belgium, France and Spain. The project is consistent with several of the European Defence Agency’s 11 major priorities in the 2018 Capability Development Plan.

”A number of European nations will start using unmanned vehicles in logistics and ISR roles, reducing the physical and cognitive load and increasing the safety of our troops. It’s important that this new capability will be well integrated with existing capabilities and force structure,” explained Kuldar Väärsi, CEO of Milrem Robotics. “It’s equally important that these new unmanned systems are safe to use and cyber protected. This is exactly the scope that iMUGS is targeting,” Väärsi added.

A Memorandum of Understanding for the cooperation has been signed by 14 parties: Milrem Robotics, GT Cyber Technologies, Safran Electronics & Defense, NEXTER Systems, Krauss-Maffei Wegmann, Diehl Defence, Bittium Wireless, Insta DefSec, (Un)Manned, dotOcean, Latvijas Mobilais Telefons, GMV Aerospace and Defence, the Estonian Military Academy and Royal Military Academy of Belgium. This unprecedented cross-border cooperation will join all expertise and skills across EU necessary to achieve a significant step forwards in this domain.

The objectives of the EDIDP programme are to contribute to the strategic autonomy of the European Union and to strengthen the cooperation between Member States. The priorities include enabling high-end operations of military forces with special focus on intelligence and secured communications and cyber. Actions include development of next generation ground combat capabilities and solutions in Artificial Intelligence, Virtual Reality and Cyber technologies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gert Hankewitz
Milrem Robotics
gert.hankewitz@milrem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye